Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCO:6932's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.99 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Mercury Biopharmaceutical Forward Dividend Yield % Related Terms
ROCO:6932 vs ZTS, UTHR: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Biopharmaceutical's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mercury Biopharmaceutical Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mercury Biopharmaceutical's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Mercury Biopharmaceutical's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Mercury Biopharmaceutical (ROCO:6932) has a Forward Dividend Yield % of 0.00% as of Jul. 14, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Mercury Biopharmaceutical and its competitors. According to the industry distribution chart, Mercury Biopharmaceutical ranks #999999 out of 511 companies in the Drug Manufacturers industry.
Is Mercury Biopharmaceutical's Forward Dividend Yield % too high?
Mercury Biopharmaceutical's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Mercury Biopharmaceutical ranks #999999 out of 511 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mercury Biopharmaceutical has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mercury Biopharmaceutical ranks #999999 out of 511 companies for Forward Dividend Yield %. This places Mercury Biopharmaceutical in the lower half of its industry. The industry median Forward Dividend Yield % is 1.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 1.99, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Mercury Biopharmaceutical and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mercury Biopharmaceutical's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$5.93 — trading 83.5% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Mercury Biopharmaceutical's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current Forward Dividend Yield % is 0.00% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?
Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued.
The current stock price of NT$5.93 is trading 83.5% below its estimated GF Value™ of NT$36.00.
GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:6932:
Forward Dividend Yield %: 0.00%
GF Value™: NT$36.00 vs. price of NT$5.93 (83.5% below fair value)
No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
25GF Score
Get the complete analysis for ROCO:6932
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6932 has been successfully added to your 
